Get started
Neurocrine Biosciences, Inc.Neurocrine Biosciences, Inc.Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

NBIX chart


Full chart

Key facts today

Barclays has maintained an Overweight rating for Neurocrine Biosciences, Inc. (NBIX) and increased its price target to $165.00 per share, up from a previous target of $160.00.
Analyze the impactAnalyze the impact

NBIX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪13.87 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
36.70
Basic EPS (TTM)
3.86 USD
Net income (FY)
‪249.70 M‬ USD
Revenue (FY)
‪1.89 B‬ USD
Shares float
‪98.54 M‬
Beta (1Y)
0.43

Employees


Employees (FY)
‪1.4 K‬
Change (1Y)
+200 +16.67%
Revenue / Employee (1Y)
‪1.35 M‬ USD
Net income / Employee (1Y)
‪178.36 K‬ USD

About Neurocrine Biosciences, Inc.


Sector
Health Technology
CEO
Kyle W. Gano
Headquarters
San Diego
Website
neurocrine.com
Founded
1992
FIGI
BBG000GJS7C1
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NBIX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where NBIX is featured.

See all sparks 

Frequently Asked Questions


The current price of NBIX is 136.53 USD — it has decreased by −0.34% in the past 24 hours. Watch Neurocrine Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neurocrine Biosciences, Inc. stocks are traded under the ticker NBIX.
NBIX stock has risen by 3.03% compared to the previous week, the month change is a 9.07% rise, over the last year Neurocrine Biosciences, Inc. has showed a 11.10% increase.
We've gathered analysts' opinions on Neurocrine Biosciences, Inc. future price: according to them, NBIX price has a max estimate of 192.00 USD and a min estimate of 121.00 USD. Watch NBIX chart and read a more detailed Neurocrine Biosciences, Inc. stock forecast: see what analysts think of Neurocrine Biosciences, Inc. and suggest that you do with its stocks.
NBIX reached its all-time high on Aug 1, 2024 with the price of 157.98 USD, and its all-time low was 1.94 USD and was reached on Nov 30, 2009. View more price dynamics on NBIX chart.
See other stocks reaching their highest and lowest prices.
NBIX stock is 1.68% volatile and has beta coefficient of 0.43. Track Neurocrine Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Neurocrine Biosciences, Inc. there?
Today Neurocrine Biosciences, Inc. has the market capitalization of ‪13.87 B‬, it has increased by 6.61% over the last week.
Yes, you can track Neurocrine Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Neurocrine Biosciences, Inc. is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
NBIX earnings for the last quarter are 1.24 USD per share, whereas the estimation was 1.51 USD resulting in a −17.62% surprise. The estimated earnings for the next quarter are 1.57 USD per share. See more details about Neurocrine Biosciences, Inc. earnings.
Neurocrine Biosciences, Inc. revenue for the last quarter amounts to ‪622.10 M‬ USD, despite the estimated figure of ‪600.64 M‬ USD. In the next quarter, revenue is expected to reach ‪630.01 M‬ USD.
NBIX net income for the last quarter is ‪129.80 M‬ USD, while the quarter before that showed ‪65.00 M‬ USD of net income which accounts for 99.69% change. Track more Neurocrine Biosciences, Inc. financial stats to get the full picture.
No, NBIX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has ‪1.40 K‬ employees. See our rating of the largest employees — is Neurocrine Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neurocrine Biosciences, Inc. EBITDA is ‪614.00 M‬ USD, and current EBITDA margin is 22.05%. See more stats in Neurocrine Biosciences, Inc. financial statements.
Like other stocks, NBIX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neurocrine Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neurocrine Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neurocrine Biosciences, Inc. stock shows the strong buy signal. See more of Neurocrine Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.